Aligos Therapeutics, Inc. Common Stock
$4.99
-$0.05 (-0.99%)
$4.82Day Range$5.45
Key Statistics
Market Cap
$31.16M
Shares Outstanding
6.2M
Primary Exchange
XNAS
Currency
USD
Type
CS
IPO Date
Oct 16, 2020
Round Lot
100
Locale
US
Trading Data
Day Open
$5.04
Day High
$5.45
Day Low
$4.82
Volume
34.5K
VWAP
$4.99
Prev Close
$5.04
Transactions
--
Acc. Volume
--
About Aligos Therapeutics, Inc. Common Stock
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES)SIC 283682 employeesONE CORPORATE DR., 2ND FLOOR, SOUTH SAN FRANCISCO, CA, 94080(800) 466-6059IPO Oct 16, 2020US / STOCKSActiveWebsite
Identifiers
- CIK
- 0001799448
- Composite FIGI
- BBG00QX7QH68
- Share Class FIGI
- BBG00QX7QH77
- Ticker Root
- ALGS
- SIC Code
- 2836
About Aligos Therapeutics, Inc. Common Stock (ALGS) Stock
Aligos Therapeutics, Inc. Common Stock (ALGS) closed the 2026-09-15 session at $4.99, down 0.99% versus the previous close (-0.05). The stock opened at $5.04 and traded between $4.82 and $5.45 during that session. Session trading volume was 34K shares. The volume-weighted average price (VWAP) is $4.99.
Aligos Therapeutics Inc is a clinical-stage biotechnology company focused on developing therapeutics for liver diseases and viral infections. Its pipeline includes drug candidates targeting chronic hepatitis B virus (HBV) infection, metabolic dysfunction-associated steatohepatitis (MASH), obesity, and coronavirus infections, with programs such as pefivfoscorvir sodium for HBV, ALG-055009 for MASH and obesity, and ALG-097558 for coronavirus infections.
Aligos Therapeutics, Inc. Common Stock has a market capitalization of $31.2 million. The company operates in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) industry classification. ALGS is listed on the XNAS exchange. The company employs approximately 82 people. Aligos Therapeutics, Inc. Common Stock is headquartered in SOUTH SAN FRANCISCO, CA. The recorded listing date is 2020-10-16.
On this page you can find market ALGS stock price data, interactive price charts with multiple timeframes (1 day to max history), company financials including income statements, balance sheets, and cash flow statements, technical indicators (SMA 50, SMA 200, EMA 20, MACD, RSI), latest news and sentiment analysis, dividend history, stock splits, short interest data, float information, and related stocks.
Explore more: View today's market movers, use the stock screener, or browse all sectors. See more stocks in the BIOLOGICAL PRODUCTS, (NO DIAGNOSTIC SUBSTANCES) sector.